Pacific Biosciences of California, Inc. (PACB) Market Cap & Valuation Ratios
Pacific Biosciences of California, Inc. (PACB) has a market cap of $655.9M and a price-to-sales ratio of 4.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PACBPacific Biosciences of California, Inc.Follow PACB — free
—
Price chart with a free account
- Market cap
- 655.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| PACB | 0.7 | — | 6.7 | — | — | +2% | -84% | -22% |
| INMD | 0.9 | 9.8 | 1.3 | 5.8 | 9.5% | -6% | 23% | 19% |
| BBNX | 0.9 | — | 5.7 | — | -7.1% | +53% | -70% | -35% |
| AHCO | 0.8 | — | 0.8 | 9.0 | 11.9% | -0.4% | -4% | -4% |
| VREX | 0.8 | — | 1.2 | 10.3 | -2.6% | +5% | 8% | 8% |
| CTKB | 0.7 | — | 3.2 | — | -1.7% | +5% | -22% | -16% |
| KIDS | 0.6 | — | 2.7 | — | -0.3% | +14% | -12% | -7% |
| TCMD | 0.5 | 21.9 | 1.3 | 11.2 | 5.0% | +17% | 10% | 15% |
| RCEL | 0.5 | — | 6.8 | — | -5.3% | +1.0% | -47% | -263% |
| MASS | 0.5 | — | 6.1 | — | 0.1% | +13% | -64% | -52% |
| CERS | 0.5 | — | 1.9 | — | -0.4% | +23% | -0.6% | -1% |
| Median of these 10 | 15.8 | 2.3 | 9.6 | -0.3% | +9% | -8% | -6% |
; EV/Sales 6.7 vs. 2.3.
Growth vs. price
each dot a company · hover or tap for valuesPacific Biosciences of California, Inc. — questions
- What is Pacific Biosciences of California, Inc.'s market cap?
- $655.9M.
- What is Pacific Biosciences of California, Inc.'s price-to-sales ratio?
- 4.1.
Every figure on this page comes from Pacific Biosciences of California, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.